Abstract Number: PB2131
Meeting: ISTH 2020 Congress
Background: Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD), high-sensitivity C-reactive protein (hs-CRP) and P-selectine (PS) after the withdrawal of anticoagulation treatment to predict the risk of venous thromboembolism (VTE) recurrence among patients with CAT.
Aims: To identify biomarkers of venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis.
Methods: Prospective multicenter study to evaluate CAT with more than 3 months of anticoagulation that was subsequently discontinued. Blood samples were taken when patients stopped the anticoagulation and 21 days later to determine the DD, PS and hs-CRP levels. All patients were followed up for 6 months to detect VTE recurrence.
Results: Between 2013 and 2015, 325 patients were evaluated and 166 patients were ultimately enrolled in the study. The mean age was 62 ± 13.5 years and nearly 40% had metastasis. Incidence of VTE recurrence at 6 months was 9.6%, 95% confidence interval [CI]: 6-15%). Male sex, ratio DD basal/DD 21 days >2, hs-CRP and PS levels after 21 days were associated with VTE recurrence. The subdistribution hazard ratios were 4.32 for male sex (95% CI 1.10-16.96), 7.53 for ratio DD >2 (95% CI 1.97-28.71), 5.15 for hs-CRP (95% CI: 1.37-19.34) and 5.60 for PS
(95% CI: 1.48-21.08).
Conclusions: This study identified that ratio DD >2, hs-CRP and PS as potential biomarkers of VTE recurrence after discontinuation of anticoagulation in CAT. A risk-adapted strategy could identify the optimal time to stop the anticoagulation in CAT patients. Funding sources: Instituto de Salud Carlos III (PI15/01085) and SETH.
To cite this abstract in AMA style:Oto J, Sánchez-López V, Arellano-Orden E, Solier-López A, Marín-Romero S, Jara-Palomares L, Elias-Hernández T, Asencio-Cruz MI, Blasco-Esquivias I, Rodriguez-de-la-Borbolla M, Sánchez-Díaz JM, Rodriguez-Martorell FJ, Medina-Badenes P, Otero-Candelera R. Biomarkers of Venous Thromboembolism Recurrence After Discontinuation of Anticoagulation for Cancer-Associated Thrombosis (HISPALIS- Study) [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/biomarkers-of-venous-thromboembolism-recurrence-after-discontinuation-of-anticoagulation-for-cancer-associated-thrombosis-hispalis-study/. Accessed May 18, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/biomarkers-of-venous-thromboembolism-recurrence-after-discontinuation-of-anticoagulation-for-cancer-associated-thrombosis-hispalis-study/